

F 2 cont'd

9. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 8.
10. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 9.
11. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 10.
12. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 11.
13. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 12.
14. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 13.
15. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 14.
16. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 15.
17. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 16.
18. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 17.
19. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 18.
20. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 19.

F 3 36. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 45.

F 4 47. The oligonucleotide of claim 45 comprising at least one 2'-O-methyl nucleotide.

REMARKS

Claims 1, 8-20, 36, 40-50 and 207-224 are pending in the application. Independent claim 1 and dependent claims 8-20, and 36 have been amended to reflect that that the synthetic oligonucleotide is selected from a group consisting of SEQ ID NOS: 7-19 and 45. The "comprising" language has been deleted from each of the claims. Claim 47 has been amended to correct an obvious typographical error.